Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SW-682 in Advanced Solid Tumors Enriched for Hippo Pathway Mutations
NCT06251310Phase 1Recruiting
- Sponsor
- SpringWorks Therapeutics
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SW-682 in solid tumor (advanced stage) and mesothelioma (5 arms), sponsored by SpringWorks Therapeutics. Primary endpoints: Incidence of Adverse Events up to 24 months, Maximum Tolerated Dose up to 24 months and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
SW-682
03
Conditions
solid tumor (advanced stage)mesothelioma
Beyond the preview
Go deeper on NCT06251310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251310.